Regulation (EU) No. 305/2011

Quant AB: Interim report July - September 2020

Monday, November 30, 2020 - 7:28am

In constant currencies, Adjusted EBITDA for the quarter was EUR 3.1 million.

Key Points: 
  • In constant currencies, Adjusted EBITDA for the quarter was EUR 3.1 million.
  • Group net loss for the year, including discontinued operations, was EUR -17.0 (-23.7) million
    On 15 September 2020, Quant announced a signing of a three-year maintenance contract with Alcoa on their Alcoa Mosjen site in Norway.
  • This information is information that Quant is obliged to make public pursuant to the EU Market Abuse Regulation.
  • The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on 30 November 2020

Public Consultation on fees for data reporting service providers (DRSP)

Friday, November 20, 2020 - 4:03pm

This consultation paper is published to seek stakeholders input on ESMAs proposals relating to fees for data reporting service provides (DRSPs) in relation to the new competences granted to ESMA under Regulation (EU) 600/2014 (MiFIR) as amended by Regulation 2019/2175 (ESA Review).

Key Points: 
  • This consultation paper is published to seek stakeholders input on ESMAs proposals relating to fees for data reporting service provides (DRSPs) in relation to the new competences granted to ESMA under Regulation (EU) 600/2014 (MiFIR) as amended by Regulation 2019/2175 (ESA Review).
  • Responding to this paper

    ESMA invites comments on all matters in this paper and in particular on the specific questions summarised in Annex 1.

  • Publication of responses

    All contributions received will be published following the close of the consultation, unless you request otherwise.

  • Any decision we make not to disclose the response is reviewable by ESMAs Board of Appeal and the European Ombudsman.

Public Consultation on fees for data reporting service providers (DRSP)

Friday, November 20, 2020 - 1:04pm

This consultation paper is published to seek stakeholders input on ESMAs proposals relating to fees for data reporting service provides (DRSPs) in relation to the new competences granted to ESMA under Regulation (EU) 600/2014 (MiFIR) as amended by Regulation 2019/2175 (ESA Review).

Key Points: 
  • This consultation paper is published to seek stakeholders input on ESMAs proposals relating to fees for data reporting service provides (DRSPs) in relation to the new competences granted to ESMA under Regulation (EU) 600/2014 (MiFIR) as amended by Regulation 2019/2175 (ESA Review).
  • Responding to this paper

    ESMA invites comments on all matters in this paper and in particular on the specific questions summarised in Annex 1.

  • Publication of responses

    All contributions received will be published following the close of the consultation, unless you request otherwise.

  • Any decision we make not to disclose the response is reviewable by ESMAs Board of Appeal and the European Ombudsman.

Travis Perkins

Friday, November 20, 2020 - 8:01am

The redemption price shall be determined and notified to holders on the second business day in London prior to the Redemption Date.

Key Points: 
  • The redemption price shall be determined and notified to holders on the second business day in London prior to the Redemption Date.
  • Payment of the redemption monies will be made through Euroclear Bank SA/NV and Clearstream Banking, S.A., in accordance with their standard procedures.
  • Unless otherwise defined herein, defined terms used have the meanings given to them in the Trust Deed.
  • For the purposes of MAR and Article 2 of Commission Implementing Regulation (EU) 2016/1055, this announcement is made by Robin Miller, General Counsel & Company Secretary of Travis Perkins plc.

Report on the risk assessment of N,N-diethyl-2- [[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1Hbenzimidazole- 1-ethanamine (isotonitazene) in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended)

Friday, November 13, 2020 - 4:03pm

This publication presents the data and findings of the risk assessment on N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1- ethanamine (isotonitazene), carried out by the extended Scientific Committee of the EMCDDA on 26 May 2020.

Key Points: 
  • This publication presents the data and findings of the risk assessment on N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1- ethanamine (isotonitazene), carried out by the extended Scientific Committee of the EMCDDA on 26 May 2020.
  • On the basis of the Risk Assessment Report, on 2 September 2020, the Commission decided that isotonitazene should be included in the definition of 'drug', in the Annex to Framework Decision 2004/757/JHA.
  • Member States shall bring into force the laws, regulations and administrative provisions necessary to comply with Commission Delegated Directive (EU) 2020/1687 by 3 June 2021.

Hexagon Interim Report 1 January - 30 September 2020

Wednesday, October 28, 2020 - 8:04am

Maria Luthstrm, Head of Sustainability and Investor Relations, Hexagon AB, +46 8 601 26 27, ir@hexagon.com

Key Points: 
  • Maria Luthstrm, Head of Sustainability and Investor Relations, Hexagon AB, +46 8 601 26 27, ir@hexagon.com
    This is information that Hexagon AB is obliged to make public pursuant to the EU Market Abuse Regulation.
  • The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on 28October 2020.

Sandvik - Interim Report Third Quarter 2020

Friday, October 16, 2020 - 12:19pm

A webcast and teleconference will be held on 16 October 2020 at 13:00 CEST.

Key Points: 
  • A webcast and teleconference will be held on 16 October 2020 at 13:00 CEST.
  • Information is available at home.sandvik/investors
    This information is information that Sandvik AB is obliged to make public pursuant to the EU Market Abuse Regulation.
  • The information was submitted for publication, through the agency of the contact person set out above, at about 11.30 CEST on 16 October 2020.

LimaCorporate Is The First Italian Company To Obtain The EU Quality Certificate Under The MDR

Thursday, July 30, 2020 - 1:00pm

SAN DANIELE DEL FRIULI,Italy, July 30, 2020 /PRNewswire/ --LimaCorporate announces that it is the first Italian company to obtain the EU Quality Management System certificate under the new European Medical Devices Regulation (MDR) from TV SD.

Key Points: 
  • SAN DANIELE DEL FRIULI,Italy, July 30, 2020 /PRNewswire/ --LimaCorporate announces that it is the first Italian company to obtain the EU Quality Management System certificate under the new European Medical Devices Regulation (MDR) from TV SD.
  • In 2015, LimaCorporate formalized the development of a line of customized products - prostheses made for the specific needs and requirements of patients.
  • It is precisely for these custom products that LimaCorporate has received this certification in accordance with the new MDR regulation.
  • Over the years, LimaCorporate has evolved, improved, and validated its quality approach to always be ahead of the curve.

LimaCorporate Is The First Italian Company To Obtain The EU Quality Certificate Under The MDR

Thursday, July 30, 2020 - 1:00pm

SAN DANIELE DEL FRIULI,Italy, July 30, 2020 /PRNewswire/ --LimaCorporate announces that it is the first Italian company to obtain the EU Quality Management System certificate under the new European Medical Devices Regulation (MDR) from TV SD.

Key Points: 
  • SAN DANIELE DEL FRIULI,Italy, July 30, 2020 /PRNewswire/ --LimaCorporate announces that it is the first Italian company to obtain the EU Quality Management System certificate under the new European Medical Devices Regulation (MDR) from TV SD.
  • In 2015, LimaCorporate formalized the development of a line of customized products - prostheses made for the specific needs and requirements of patients.
  • It is precisely for these custom products that LimaCorporate has received this certification in accordance with the new MDR regulation.
  • Over the years, LimaCorporate has evolved, improved, and validated its quality approach to always be ahead of the curve.

Boliden: Q2 Interim Report 2020

Wednesday, July 22, 2020 - 7:15am

Please find enclosed the full report.

Key Points: 
  • Please find enclosed the full report.
  • The Interim Report will be presented via a webcast/conference call on Wednesday, July 22nd at 09:30 (CET).
  • This information is information that Boliden AB is obliged to make public pursuant to the EU Market Abuse Regulation.
  • The information was submitted for publication, through the agency of Director Investor Relations, at 07.45 CET on the 22ndof July 2020.